Search

Your search keyword '"Mitsuhashi, Kenjiro"' showing total 31 results
Start Over Author "Mitsuhashi, Kenjiro"
31 results on '"Mitsuhashi, Kenjiro"'

1. NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia

Author

Marumo, Atsushi, Wakita, Satoshi, Morita, Kaoru, Oh, Iekuni, Kako, Shinichi, Toya, Takashi, Najima, Yuho, Doki, Noriko, Kanda, Junya, Kuroda, Junya, Mori, Shinichiro, Satake, Atsushi, Usuki, Kensuke, Uoshima, Nobuhiko, Kobayashi, Yutaka, Kawata, Eri, Nagao, Yuhei, Shono, Katsuhiro, Shibusawa, Motoharu, Tadokoro, Jiro, Hagihara, Masao, Uchiyama, Hitoji, Kubota, Yasushi, Kimura, Shinya, Motomura, Sayuri, Hashimoto, Akiko, Muto, Hideharu, Sato, Eriko, Ogata, Masao, Mitsuhashi, Kenjiro, Ando, Jun, Date, Kenta, Fujiwara, Yusuke, Terada, Kazuki, Yui, Shunsuke, Arai, Kunihito, Kitano, Tomoaki, Miyata, Miho, Ohashi, Kazuteru, Kanda, Yoshinobu, and Yamaguchi, Hiroki

Published
2022
Full Text
View/download PDF

2. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia

Author

Wakita, Satoshi, Sakaguchi, Masahiro, Oh, Iekuni, Kako, Shinichi, Toya, Takashi, Najima, Yuho, Doki, Noriko, Kanda, Junya, Kuroda, Junya, Mori, Shinichiro, Satake, Atsushi, Usuki, Kensuke, Ueki, Toshimitsu, Uoshima, Nobuhiko, Kobayashi, Yutaka, Kawata, Eri, Tajika, Kenji, Nagao, Yuhei, Shono, Katsuhiro, Shibusawa, Motoharu, Tadokoro, Jiro, Kayamori, Kensuke, Hagihara, Masao, Uchiyama, Hitoji, Uchida, Naoyuki, Kubota, Yasushi, Kimura, Shinya, Nagoshi, Hisao, Ichinohe, Tatsuo, Kurosawa, Saiko, Motomura, Sayuri, Hashimoto, Akiko, Muto, Hideharu, Sato, Eriko, Ogata, Masao, Mitsuhashi, Kenjiro, Ando, Jun, Marumo, Atsushi, Omori, Ikuko, Fujiwara, Yusuke, Terada, Kazuki, Yui, Shunsuke, Arai, Kunihito, Kitano, Tomoaki, Miyata, Miho, Kurosawa, Akiyo, Mizoguchi, Ayumi, Komatsu, Norio, Fukuda, Takahiro, Ohashi, Kazuteru, Kanda, Yoshinobu, Inokuchi, Koiti, and Yamaguchi, Hiroki

Published
2022
Full Text
View/download PDF

3. Comparison of Cyclophosphamide Combined with Total Body Irradiation, Oral Busulfan, or Intravenous Busulfan for Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia

Author

Mitsuhashi, Kenjiro, Kako, Shinichi, Shigematsu, Akio, Atsuta, Yoshiko, Doki, Noriko, Fukuda, Takahiro, Kanamori, Heiwa, Onizuka, Makoto, Takahashi, Satoshi, Ozawa, Yukiyasu, Kurokawa, Mineo, Inoue, Yoshiko, Nagamura-Inoue, Tokiko, Morishima, Yasuo, Mizuta, Shuichi, and Tanaka, Junji

Published
2016
Full Text
View/download PDF

4. Allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia who had central nervous system involvement: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation

Author

Shigematsu, Akio, Kako, Shinichi, Mitsuhashi, Kenjiro, Iwato, Koji, Uchida, Naoyuki, Kanda, Yoshinobu, Fukuda, Takahiro, Sawa, Masashi, Senoo, Yasushi, Ogawa, Hiroyasu, Miyamura, Koichi, Takada, Satoru, Nagamura-Inoue, Tokiko, Morishima, Yasuo, Ichinohe, Tatsuo, Atsuta, Yoshiko, Mizuta, Shuichi, and Tanaka, Junji

Published
2017
Full Text
View/download PDF

5. Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia

Author

Wakita, Satoshi, primary, Marumo, Atsushi, additional, Morita, Kaoru, additional, Kako, Shinichi, additional, Toya, Takashi, additional, Najima, Yuho, additional, Doki, Noriko, additional, Kanda, Junya, additional, Kuroda, Junya, additional, Mori, Shinichiro, additional, Satake, Atsushi, additional, Usuki, Kensuke, additional, Ueki, Toshimitsu, additional, Uoshima, Nobuhiko, additional, Kobayashi, Yutaka, additional, Kawata, Eri, additional, Nakayama, Kazutaka, additional, Nagao, Yuhei, additional, Shono, Katsuhiro, additional, Shibusawa, Motoharu, additional, Tadokoro, Jiro, additional, Hagihara, Masao, additional, Uchiyama, Hitoji, additional, Uchida, Naoyuki, additional, Kubota, Yasushi, additional, Kimura, Shinya, additional, Nagoshi, Hisao, additional, Ichinohe, Tatsuo, additional, Kurosawa, Saiko, additional, Motomura, Sayuri, additional, Hashimoto, Akiko, additional, Muto, Hideharu, additional, Sato, Eriko, additional, Ogata, Masao, additional, Mitsuhashi, Kenjiro, additional, Ando, Jun, additional, Tashiro, Haruko, additional, Sakaguchi, Masahiro, additional, Yui, Shunsuke, additional, Arai, Kunihito, additional, Kitano, Tomoaki, additional, Miyata, Miho, additional, Arai, Haruka, additional, Kanda, Masayuki, additional, Itabashi, Kako, additional, Fukuda, Takahiro, additional, Kanda, Yoshinobu, additional, and Yamaguchi, Hiroki, additional

Published
2023
Full Text
View/download PDF

7. Mutational Analysis of DNMT3A Improves the Prognostic Stratification Using NPM1/FLT3-ITD Genotypes in Patients with Acute Myeloid Leukemia

Author

Marumo, Atsushi, primary, Wakita, Satoshi, additional, Morita, Kaoru, additional, Kako, Shinichi, additional, Toya, Takashi, additional, Najima, Yuho, additional, Doki, Noriko, additional, Kanda, Junya, additional, Kuroda, Junya, additional, Mori, Shin-Ichiro, additional, Satake, Atsushi, additional, Usuki, Kensuke, additional, Ueki, Toshimitsu, additional, Uoshima, Nobuhiko, additional, Kobayashi, Yutaka, additional, Kawata, Eri, additional, Nakayama, Kazutaka, additional, Nagao, Yuhei, additional, Shono, Katsuhiro, additional, Shibusawa, Motoharu, additional, Tadokoro, Jiro, additional, Hagihara, Masao, additional, Uchiyama, Hitoji, additional, Uchida, Naoyuki, additional, Kubota, Yasushi, additional, Kimura, Shinya, additional, Nagoshi, Hisao, additional, Ichinohe, Tatsuo, additional, Kurosawa, Saiko, additional, Motomura, Sayuri, additional, Akiko, Hashimoto, additional, Muto, Hideharu, additional, Sato, Eriko, additional, Ogata, Masao, additional, Mitsuhashi, Kenjiro, additional, Ando, Jun, additional, Tashiro, Haruko, additional, Sakaguchi, Masahiro, additional, Yui, Shunsuke, additional, Arai, Kunihito, additional, Kitano, Tomoaki, additional, Miyata, Miho, additional, Fukuda, Takahiro, additional, Kanda, Yoshinobu, additional, and Yamaguchi, Hiroki, additional

Published
2022
Full Text
View/download PDF

9. Development of diffuse large B‐cell lymphoma during dupilumab treatment in a patient with atopic dermatitis: A case report

Author

Uchida, Hideaki, primary, Kamata, Masahiro, additional, Nagata, Mayumi, additional, Fukaya, Saki, additional, Hayashi, Kotaro, additional, Fukuyasu, Atsuko, additional, Tanaka, Takamitsu, additional, Ishikawa, Takeko, additional, Ohnishi, Takamitsu, additional, Mitsuhashi, Kenjiro, additional, and Tada, Yayoi, additional

Published
2021
Full Text
View/download PDF

12. Phase I study of cellular therapy using ex vivo expanded natural killer cells from autologous peripheral blood mononuclear cells combined with rituximab-containing chemotherapy for relapsed CD20-positive malignant lymphoma patients

Author

Tanaka, Junji, primary, Tanaka, Norina, additional, Wang, Yan-Hua, additional, Mitsuhashi, Kenjiro, additional, Ryuzaki, Michiko, additional, Iizuka, Yuki, additional, Watanabe, Aya, additional, Ishiyama, Midori, additional, Shinohara, Akihito, additional, Kazama, Hiroshi, additional, Hagiwara, Shotaro, additional, Yoshinaga, Kentaro, additional, Kougen, Yumi, additional, Kobayashi, Hirohito, additional, Kanno, Hitoshi, additional, and Shiseki, Masayuki, additional

Published
2019
Full Text
View/download PDF

13. Mutational Analysis of DNMT3AImproves the Prognostic Stratification Using NPM1/FLT3-ITD Genotypes in Patients with Acute Myeloid Leukemia

Author

Marumo, Atsushi, Wakita, Satoshi, Morita, Kaoru, Kako, Shinichi, Toya, Takashi, Najima, Yuho, Doki, Noriko, Kanda, Junya, Kuroda, Junya, Mori, Shin-Ichiro, Satake, Atsushi, Usuki, Kensuke, Ueki, Toshimitsu, Uoshima, Nobuhiko, Kobayashi, Yutaka, Kawata, Eri, Nakayama, Kazutaka, Nagao, Yuhei, Shono, Katsuhiro, Shibusawa, Motoharu, Tadokoro, Jiro, Hagihara, Masao, Uchiyama, Hitoji, Uchida, Naoyuki, Kubota, Yasushi, Kimura, Shinya, Nagoshi, Hisao, Ichinohe, Tatsuo, Kurosawa, Saiko, Motomura, Sayuri, Akiko, Hashimoto, Muto, Hideharu, Sato, Eriko, Ogata, Masao, Mitsuhashi, Kenjiro, Ando, Jun, Tashiro, Haruko, Sakaguchi, Masahiro, Yui, Shunsuke, Arai, Kunihito, Kitano, Tomoaki, Miyata, Miho, Fukuda, Takahiro, Kanda, Yoshinobu, and Yamaguchi, Hiroki

Published
2022
Full Text
View/download PDF

14. Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine

Author

Isono, Noriko, primary, Imai, Yoichi, additional, Watanabe, Aya, additional, Moriya, Keiichi, additional, Tamura, Hideto, additional, Inokuchi, Koiti, additional, Asano, Chihiro, additional, Masuda, Michihiko, additional, Shimura, Hanae, additional, Mitsuhashi, Kenjiro, additional, Kazama, Hiroshi, additional, Sugimori, Hiroki, additional, Motoji, Toshiko, additional, and Tanaka, Junji, additional

Published
2015
Full Text
View/download PDF

20. Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine.

Author

Isono, Noriko, Imai, Yoichi, Watanabe, Aya, Moriya, Keiichi, Tamura, Hideto, Inokuchi, Koiti, Asano, Chihiro, Masuda, Michihiko, Shimura, Hanae, Mitsuhashi, Kenjiro, Kazama, Hiroshi, Sugimori, Hiroki, Motoji, Toshiko, and Tanaka, Junji

Subjects
LYMPHOMA treatment, B cell lymphoma, CYTOMEGALOVIRUS disease treatment, RITUXIMAB, LEUKOCYTES, ANTIGENS, UNIVARIATE analysis, TUMOR treatment
Abstract

The article discusses the cytomegalovirus (CMV) reactivation in patients with low-grade B-cell lymphoma treated with bendamustine. Noted is the detection of pp65 antigen in peripheral blood leukocytes, and a univariate analysis of the characteristics of CMV reactivation patients to estimate the risk factors. Findings showed no significant difference in number of prior regimens, disease stage, or number of times of rituximab treatments between CMV-negative and CMV-positive patients.

Published
2016
Full Text
View/download PDF

23. Prognostic impact of CEBPAbZIP domain mutation in acute myeloid leukemia

Author

Wakita, Satoshi, Sakaguchi, Masahiro, Oh, Iekuni, Kako, Shinichi, Toya, Takashi, Najima, Yuho, Doki, Noriko, Kanda, Junya, Kuroda, Junya, Mori, Shinichiro, Satake, Atsushi, Usuki, Kensuke, Ueki, Toshimitsu, Uoshima, Nobuhiko, Kobayashi, Yutaka, Kawata, Eri, Tajika, Kenji, Nagao, Yuhei, Shono, Katsuhiro, Shibusawa, Motoharu, Tadokoro, Jiro, Kayamori, Kensuke, Hagihara, Masao, Uchiyama, Hitoji, Uchida, Naoyuki, Kubota, Yasushi, Kimura, Shinya, Nagoshi, Hisao, Ichinohe, Tatsuo, Kurosawa, Saiko, Motomura, Sayuri, Hashimoto, Akiko, Muto, Hideharu, Sato, Eriko, Ogata, Masao, Mitsuhashi, Kenjiro, Ando, Jun, Marumo, Atsushi, Omori, Ikuko, Fujiwara, Yusuke, Terada, Kazuki, Yui, Shunsuke, Arai, Kunihito, Kitano, Tomoaki, Miyata, Miho, Kurosawa, Akiyo, Mizoguchi, Ayumi, Komatsu, Norio, Fukuda, Takahiro, Ohashi, Kazuteru, Kanda, Yoshinobu, Inokuchi, Koiti, and Yamaguchi, Hiroki

Abstract

Mutations of CCAAT/enhancer binding protein alpha (CEBPAmu) are found in 10-15% of de novoacute myeloid leukemia (AML) cases. Double-mutated CEBPA(CEBPAdm) is associated with a favorable prognosis; however, single-mutated CEBPA(CEBPAsm) does not appear to improve prognosis. We investigated the CEBPAmu for prognosis in 1028 AML patients, registered in the Multi-center Collaborative Program for Gene Sequencing of Japanese AML. It was found that CEBPAmu in the basic leucine zipper domain (bZIP) was strongly associated with a favorable prognosis, but CEBPAmu out of the bZIP domain was not. The presence of CEBPAmu in bZIP was a strong indicator of a higher chance of achieving complete remission (p<0.001), better overall survival (OS; p<0.001) and a lower risk of relapse (p<0.001). The prognostic significance of CEBPAmu in bZIP was also observed in the subgroup with CEBPAsm(all patients, OS: p=0.008; the cumulative incidence of relapse (CIR): p=0.063. patients aged ≤70 years and withintermediate-risk karyotype, OS: p=0.008; CIR: p=0.026). Multivariate analysis of 744 patients aged ≤70 years showed that CEBPAmu in bZIP was the most potent predictor of OS (hazard ratio: 0.3287; p<0.001). CEBPAdm was validated as a cofounding factor, which was overlapping with CEBPAmu in bZIP. In summary, these findings indicate that CEBPAmu in bZIP is a potent marker for AML prognosis. It holds potential in the refinement of treatment stratification and the development of targeted therapeutic approaches in CEBPAmutated AML.

Published
2021
Full Text
View/download PDF

24. L265P Mutation of the MYD88 Gene Is Frequent in Waldenström’s Macroglobulinemia and Its Absence in Myeloma.

Author

Mori, Naoki, Ohwashi, Mari, Yoshinaga, Kentaro, Mitsuhashi, Kenjiro, Tanaka, Norina, Teramura, Masanao, Okada, Michiko, Shiseki, Masayuki, Tanaka, Junji, and Motoji, Toshiko

Subjects
GENETIC mutation, MYELOMA proteins, BONE marrow, NUCLEOTIDE sequence, WALDENSTROM'S macroglobulinemia, POLYMERASE chain reaction, ALLELES
Abstract

L265P mutation in the MYD88 gene has recently been reported in Waldenström’s macroglobulinemia; however the incidence has been different according to the methods used. To determine the relevance and compare the incidence by different methods, we analyzed the L265P mutation in bone marrow mononuclear cells from lymphoid neoplasms. We first performed cloning and sequencing in 10 patients: 8 Waldenström’s macroglobulinemia; 1 non-IgM-secreting lymphoplasmacytic lymphoma; and 1 low grade B-cell lymphoma with monoclonal IgG protein. The L265P mutation was detected in only 1/8 Waldenström’s macroglobulinemia patients (2 of 9 clones). To confirm these results, direct sequencing was performed in the 10 patients and an additional 17 Waldenström’s macroglobulinemia patients and 1 lymphoplasmacytic lymphoma patient. Nine of 28 patients (7/25 Waldenström’s macroglobulinemia, 1/2 lymphoplasmacytic lymphoma, and B-cell lymphoma) harbored the mutation. We next tested for the mutation with BSiE1 digestion and allele-specific polymerase chain reaction in the 28 patients and 38 patients with myeloma. Aberrant bands corresponding to the mutation were detected by BSiE1 digestion in 19/25 patients with Waldenström’s macroglobulinemia (76%), 1/2 lymphoplasmacytic lymphoma and B-cell lymphoma, but not in the 38 myeloma patients. The L265P mutation was more frequent in patients with Waldenström’s macroglobulinemia than in those with myeloma (p=1.3x10-10). The mutation was detected by allele-specific polymerase chain reaction in 18/25 Waldenström’s macroglobulinemia patients (72%). In the 25 Waldenström’s macroglobulinemia patients, the L265P was more frequently detected by BSiE1 digestion than by direct sequencing (p=5.3x10-4), and in males (15/16, 94%) than in females (4/9, 44%) (p=1.2x10-2). No siginificant difference was observed in the incidence of the L265P mutation between BSiE1 digestion and allele-specific polymerase chain reaction (p=0.32). These results suggest that the L265P mutation is involved in the majority of Waldenström’s macroglobulinemia. BSiE1 digestion and allele-specific polymerase chain reaction may detect a small fraction of mutated cells in some cases. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

25. Knockdown of a Wnt Receptor FZD1reduces MDR1/P-Glycoprotein Expression in Human Leukemia Cells through the Wnt/β-Catenin Signaling Pathway

Author

Wang, Yan-Hua, Motoji, Toshiko, Imai, Yoichi, Shiseki, Masayuki, Mitsuhashi, Kenjiro, Ding, Ye, and Tanaka, Junji

Abstract

Background:Multidrug resistance (MDR) expressed in leukemia cells is a major obstacle in the use of chemotherapy for leukemia treatment. The Wnt signaling pathway is essential for maintenance, activation, regulated self-renewal and proliferation in both normal hematopoietic and leukemia cells. Frizzled-1 (FZD1), part of the Wnt receptor family, has been reported to be associated with drug resistance in a number of solid cancers, but the involvement of FZD1 in leukemia is yet to be studied. Here, we investigated whether FZD1 is associated with MDR1/P-glycoprotein (P-gp) in multidrug resistance of leukemic cell lines and examined FZD1and MDR1/P-gp expression levels in AML cells from patients.

Published
2014
Full Text
View/download PDF

27. [Low psoas muscle index as independent poor prognostic factor for diffuse large B-cell lymphoma in elderly patients].

Author

Arai K, Mitsuhashi K, Honjo Y, Kurachi M, Komiya Y, Arao T, and Sato H

Subjects
Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cyclophosphamide therapeutic use, Doxorubicin therapeutic use, Humans, Prednisone therapeutic use, Prognosis, Retrospective Studies, Rituximab therapeutic use, Vincristine therapeutic use, Lymphoma, Large B-Cell, Diffuse diagnosis, Lymphoma, Large B-Cell, Diffuse drug therapy, Psoas Muscles diagnostic imaging
Abstract

Sarcopenia is associated with poor clinical outcomes in elderly patients with diffuse large B-cell lymphoma (DLBCL). However, the clinical significance and optimal assessment of sarcopenia remain unclear. We retrospectively evaluated the prognostic value of low skeletal muscle mass based on the psoas muscle index (PMI) in patients with DLBCL aged 70 years and older treated with R-CHOP therapy. We included 71 patients, including 27 classified under low PMI. There were no differences in baseline characteristics (body mass index, lactate dehydrogenase, performance status [PS], stage, revised-IPI, relative dose intensity) and overall response rate between the low and high PMI groups. The low PMI group had a significantly worse overall survival (OS, p=0.015), but not progression-free survival (PFS, p=0.252), compared with the high PMI group. On multivariate analysis, low PMI and PS were independent negative prognostic factors for OS. Subgroup analysis revealed that the low PS groups had significantly worse PFS regardless of the PMI status. The low PMI and low PS group had markedly poorer OS than all the other groups. However, the poor prognosis associated with low PS was overcome by a high PMI.

Published
2022
Full Text
View/download PDF

28. Phase I study of cellular therapy using ex vivo expanded natural killer cells from autologous peripheral blood mononuclear cells combined with rituximab-containing chemotherapy for relapsed CD20-positive malignant lymphoma patients.

Author

Tanaka J, Tanaka N, Wang YH, Mitsuhashi K, Ryuzaki M, Iizuka Y, Watanabe A, Ishiyama M, Shinohara A, Kazama H, Hagiwara S, Yoshinaga K, Kougen Y, Kobayashi H, Kanno H, and Shiseki M

Subjects
Antigens, CD20, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Humans, Killer Cells, Natural, Rituximab, Leukocytes, Mononuclear, Lymphoma drug therapy
Published
2020
Full Text
View/download PDF

29. [Angioimmunoblastic T-cell lymphoma with marked polyclonal plasmacytosis in peripheral blood and bone marrow mimicking plasma cell leukemia].

Author

Mitsuhashi K, Shiseki M, Ishiyama M, Kondo T, Kazama H, Yasunami T, Okamura T, Yoshinaga K, Mori N, Teramura M, Masuda A, and Motoji T

Subjects
Aged, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cyclophosphamide administration & dosage, Doxorubicin administration & dosage, Humans, Immunoblastic Lymphadenopathy drug therapy, Immunoblastic Lymphadenopathy etiology, Interleukin-10, Interleukin-6, Leukemia, Plasma Cell, Lymphoma, T-Cell drug therapy, Lymphoma, T-Cell etiology, Male, Prednisolone administration & dosage, Treatment Outcome, Vincristine administration & dosage, Bone Marrow pathology, Immunoblastic Lymphadenopathy blood, Immunoblastic Lymphadenopathy pathology, Lymphoma, T-Cell blood, Lymphoma, T-Cell pathology, Plasma Cells pathology
Abstract

A 70-year-old man was admitted to our hospital with fever, generalized lymphadenopathy and hypoxia in October 2009. Blood examination demonstrated leukocytosis, anemia, thrombocytopenia and hyper γ-globulinemia. Peripheral blood and bone marrow smear showed marked plasma cell proliferation mimicking plasma cell leukemia. However, flow cytometric analysis showed that plasma cells were of polyclonal origin and M-protein was not detected by immunofixation of serum protein. Elevations of soluble interleukin 2 receptor and serum IL-6 were observed. A heavy Epstein-Barr viral load was detected in serum by real-time PCR. Biopsy was obtained from the right inguinal lymph node. The pathological diagnosis was angioimmunoblastic T-cell lymphoma (AITL) and rearrangement of the T-cell receptor Cβ1 gene was detected. The patient was treated with CHOP therapy, and all clinical manifestations, including fever, lymphadenopathy, anemia, thrombocytopenia, hyper γ-globulinemia, plasmacytosis and hypoxia, were improved. Only a few reported cases have demonstrated AITL with marked polyclonal plasmacytosis. Although pathological mechanisms of plasmacytosis in AITL patients have not been fully elucidated, it is suggested that IL-6 and IL-10 were involved in its pathogenesis in the present case.

Published
2011

30. [Successful treatment with cetuximab combination chemotherapy in a case of FOLFOX-refractory rectal cancer with previously unresectable multiple liver metastases leading to complete resection].

Author

Mitsuhashi K, Matsusaka S, Mizunuma N, Ichimura T, Ozaka M, Ogura M, Shinozaki E, Suenaga M, Chin K, Fujimoto Y, Saiura A, Yamamoto N, and Hatake K

Subjects
Adult, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols pharmacology, Camptothecin administration & dosage, Camptothecin analogs & derivatives, Cetuximab, Drug Resistance, Neoplasm, Fluorouracil administration & dosage, Fluorouracil pharmacology, Humans, Leucovorin administration & dosage, Leucovorin pharmacology, Liver Neoplasms drug therapy, Male, Organoplatinum Compounds pharmacology, Rectal Neoplasms pathology, Antibodies, Monoclonal administration & dosage, Antineoplastic Agents administration & dosage, Liver Neoplasms secondary, Liver Neoplasms surgery, Rectal Neoplasms drug therapy, Rectal Neoplasms surgery
Abstract

Unlabelled: Most colorectal cancer patients with liver metastases are not resectable upon initial diagnosis. Recently, chemotherapy improves overall survival of initially unresectable patients by allowing tumor downstaging and complete resection. We report a FOLFOX-refractory rectal cancer patient with unresectable multiple liver metastases, whose tumors could be downstaged and completely resected after initiation of FOLFIRI with cetuximab., Case: A 41-year-old male demonstrated rectal cancer with unresectable multiple liver metastases. He was treated by FOLFOX4 therapy as first-line chemotherapy. After initiating 14 courses, he was treated by FOLFIRI with cetuximab because of disease progression. After initiation of chemotherapy, radiographic examination demonstrated remarkable reduction of primary rectal tumor and metastatic liver tumors. He underwent complete rectal tumor resection after 13 courses of chemotherapy, and metastatic liver tumor resection after 18 courses of chemotherapy.

Published
2010

31. [Spinal epidural abscess with persistent increase in cerebrospinal fluid protein: a case study].

Author

Mitsuhashi K, Nakamura T, Hashimoto S, Uchiyama S, and Iwata M

Subjects
Aged, Epidural Abscess diagnosis, Epidural Abscess microbiology, Humans, Magnetic Resonance Imaging, Male, Renal Dialysis, Tomography, X-Ray Computed, Cerebrospinal Fluid Proteins cerebrospinal fluid, Epidural Abscess cerebrospinal fluid, Methicillin Resistance, Staphylococcal Infections cerebrospinal fluid, Staphylococcus aureus drug effects
Abstract

A 67-year-old man under hemodialysis treatment developed neck stiffness, fever and conscious disturbances. The patient was infected with Methicilin-resistant Staphylococcus aureus (MRSA) sepsis caused by an infection on a dialysis shunt. On admission, he was diagnosed with bacterial meningoencephalitis and underwent a series of antibiotic chemotherapies. The treatment brought cell count in the cerebrospinal fluid to a subnormal level but his clinical status did not improve. The patient continued to have high level of cerebrospinal fluid protein (898 mg/dl). Cervical MRI demonstrated two abscesses deep in the neck as well as in the epidural region of the cervical spinal cord, from C2 to C5 vertebral levels. Based on these findings, spinal epidural abscess (SEA) was diagnosed. Intensive antibiotic chemotherapy especially targeted for MRSA could eradicate abscesses and improve clinical status. However, persistent high protein level in the cerebrospinal fluid could suggest SEA.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results